[EN] NOVEL CYANINE DERIVATIVES HAVING MESO-REACTIVE FUNCTIONAL GROUP AT POLYMETHINE CHAIN AND PREPARATION METHOD THEREOF [FR] NOUVEAUX DÉRIVÉS DE CYANINE AYANT UN GROUPE FONCTIONNEL MÉSO-RÉACTIF AU NIVEAU D'UNE CHAÎNE DE POLYMÉTHINE ET LEUR PROCÉDÉ DE PRÉPARATION
The invention provides fluorescent sensors for the selective detection of a metal such as copper. The sensors may be considered to be derivatives of cyanine, fluorescein, rhodamine, rhodol, Tokyo green, or BODIPY. The sensors find particular use in detecting copper in cells and living animals.
NOVEL ORGANIC COMPOUND, NEAR-INFRARED FLUORESCENT CONSTANT MEDIUM CONTAINING SAME, AND METHOD FOR NANO-GRANULATING CONSTANT MEDIUM
申请人:COLLEGE OF MEDICINE POCHON CHA UNIVERISTY INDUSTRY- ACADEMIC COOPERATION FOUNDATION
公开号:US20180327357A1
公开(公告)日:2018-11-15
The present invention relates to a novel organic compound, a near-infrared fluorescent constant medium containing the same, and a method for nano-granulating the constant medium.
competitively interact with the active site of tyrosine kinase receptors to suppress the downstream signalingpathway to inhibit tumor proliferation. In this study, in order to improve the tumor cell targeting ability of EGFR-TKI, EGFR-TKI erlotinib was conjugated with the cancer cell-targeting heptamethinecyaninedyes to form seventeen novel erlotinib-dye conjugates. The efficiency of tumor targeting properties
Accessing Structurally Diverse Near-Infrared Cyanine Dyes for Folate Receptor-Targeted Cancer Cell Staining
作者:Sandra G. König、Roland Krämer
DOI:10.1002/chem.201700026
日期:2017.7.12
for the development of small‐molecule‐based cancer imagingagents considering that the FR is highly overexpressed on the surface of many cancer cell types. FR‐targeted conjugates of near‐infrared (NIR) emissive cyanine dyes are in advanced clinical trials for fluorescence‐guided surgery and are valuable research tools for optical molecular imaging in animal models. Only a small number of promising conjugates
Prostate cancer (PCa) is the most frequent malignant cancer among men in the USA, leading to substantial morbidity and mortality, while the existing treatments have restricted therapeutic benefits for patients with hormone-refractory PCa (HRPC) and metastatic PCa. Recent studies show that advanced PCa exhibits an increase in the expression of monoamine oxidase A (MAOA) which is a mitochondria enzyme